DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
Rockville, MD 20857

ANDA 090763

Mylan Pharmaceuticals, Inc.
U.S. Agent for: Matrix Laboratories Limited
Attention: Keith J. Giunta
Associate director, Regulatory Affairs
781 Chestnut Ridge Road
P.O. Box 4310
Morgantown, WV 26504

Dear Sir:

This is in reference to your abbreviated new drug application (ANDA) dated July 30, 2008, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Lansoprazole Delayed-release Capsules, USP 15 mg and 30 mg.

Reference is also made to your amendments dated October 6, October 8, October 16, October 27, November 6, and November 8, 2009.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the ANDA is approved, effective on the date of this letter. The Division of Bioequivalence has determined your Lansoprazole Delayed-release Capsules USP, 15 mg and 30 mg, to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Prevacid Delayed-release Capsules, 15 mg and 30 mg, respectively, of Takeda Pharmaceuticals North America, Inc.

Your dissolution testing should be conducted according to the USP 31 monograph for Lansoprazole Delayed-release Capsules.

The listed drug product (RLD) referenced in your application, Prevacid Delayed-release Capsules, 15 mg and 30 mg of Takeda Pharmaceuticals North America is subject to a period of patent protection. The following unexpired patent and its expiration date (with pediatric exclusivity extension) are currently listed

in the agency's publication titled Approved Drug Products with Therapeutic Equivalence Evaluations, the "Orange Book" for this drug product:

U.S. Patent Number	Expiration Date
5,013,743 (the '743 patent)	August 12, 2010

With respect to the '743 patent, your ANDA contains statements under section 505(j)(2)(A)(viii) of the Act indicating that this is a method-of-use patent, and that this patent does not claim any proposed indication for which you are seeking approval under your ANDA.

Under section 506A of the Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

We note that if FDA requires a Risk Evaluation & Mitigation Strategy (REMS) for a listed drug, an ANDA citing that listed drug also will be required to have a REMS, See 505-1(i).

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Division of Drug Marketing, Advertising, and Communications with a completed Form FDA 2253 at the time of their initial use.

Within 14 days of the date of this letter, submit updated content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format, as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical in content to the approved labeling. Upon receipt and verification, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission as "***Miscellaneous Correspondence - SPL for Approved ANDA 090763***".

Sincerely yours,

{See appended electronic signature page}

Gary Buehler
Director
Office of Generic Drugs
Center for Drug Evaluation and Research

Application Type/Number	Submission Type/Number	Submitter Name	Product Name
ANDA-90763	ORIG-1	MATRIX LABORATORIES LTD	LANSOPRAZOLE

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ROBERT L WEST
11/10/2009
Deputy Director, for Gary Buehler